Barrett Burke Thomas bought $85,600 worth of shares (10,000 units at $8.56) (SEC Form 4)

$PLSE
Medical/Dental Instruments
Health Care
Get the next $PLSE alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Barrett Burke Thomas

(Last) (First) (Middle)
C/O PULSE BIOSCIENCES, INC.
3957 POINT EDEN WAY

(Street)
HAYWARD CA 94545

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Pulse Biosciences, Inc. [ PLSE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
05/20/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/20/2024 P 10,000 A $8.56(1) 10,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Volume-weighted average price.
/s/ Kenneth B. Stratton, as Attorney-in-Fact 05/22/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $PLSE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PLSE

DatePrice TargetRatingAnalyst
2/10/2022$43.00 → $20.00Buy
HC Wainwright & Co.
11/16/2021$46.00 → $43.00Buy
HC Wainwright & Co.
7/27/2021$28.00Overweight
Stephens & Co.
More analyst ratings

$PLSE
Press Releases

Fastest customizable press release news feed in the world

See more
  • Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 24th Annual Needham Virtual Health Care Conference. Pulse Biosciences' Management is scheduled to present on Thursday, April 10, 2025, at 9:30 am ET. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 and providing conference ID 5548579. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® P

    $PLSE
    Medical/Dental Instruments
    Health Care

$PLSE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PLSE
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PLSE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PLSE
SEC Filings

See more

$PLSE
Leadership Updates

Live Leadership Updates

See more
  • Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

    Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon

    $AXTA
    $PLSE
    $TFX
    Paints/Coatings
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

    Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

    Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech

    $PLSE
    Medical/Dental Instruments
    Health Care

$PLSE
Financials

Live finance-specific insights

See more
  • Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 and providing conference ID 5548579. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® P

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with commercial use expected to begin in the coming quarters. The Company expects to commence a pivotal clinical trial in mid-2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in

    $PLSE
    Medical/Dental Instruments
    Health Care

$PLSE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more